Cited by 305Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and MetabolismBreast Cancer Treatment Studies

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells

Open access

Samanta, Debangshu, Park, Youngrok, Ni, Xuhao, Li, Huili, Zahnow, Cynthia A., Gabrielson, Edward, Pan, Fan, Semenza, Gregg L.·2018·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1718197115PMC PMC5819443

Open this paper in CoChat — free account Open PDF

Abstract

Significance Cytotoxic chemotherapy is frequently used in patients with triple-negative breast cancer (TNBC). Although patients initially respond to the treatment, the cancer often comes back and kills the patient. Recent studies have demonstrated that cancer cells express genes that protect them from killing by immune cells, but the stimulus that prompts this response is unknown. We show that when TNBC cells are treated with chemotherapy, the surviving cells turn on genes that enable them to escape killing by the immune system. We identify hypoxia-inducible factors (HIFs), which are known to promote metastasis of TNBC, as responsible for this countertherapeutic effect. We show that coadministration of an HIF inhibitor with chemotherapy blocks the ability of surviving TNBC cells to evade the immune system.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1073/pnas.1718197115

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

3 retracted

RETRACTED: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells
Samanta, D., Gilkes, D. M., Chaturvedi, P., Xiang, L., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421438111 · Cited by 460
Self-citation
Retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
Self-citation
Retracted
RETRACTED ARTICLE: HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs
Zhang, H., Wong, C. C. L., Wei, H., Gilkes, D. M., Korangath, P., Chaturvedi, P., Schito, L., Chen, J., Krishnamachary, B., Winnard, P. T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.365 · Cited by 326
Self-citation
Retracted
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Remarkable therapeutic responses to anti-PD1 or antiPDL1 antibodies have occurred in a minority of patients with melanoma, non-small cell lung cancer, and renal carcinoma (22, 23).”
Background

Show all 63 references

Sorted by citations

Hypoxia-inducible factors: cancer progression and clinical translation
Wicks, E. E., & Semenza, G. L. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159839 · Cited by 626
Self-citation
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape
Wu, Q., Li, Y., Nepovimová, E., Heger, Z., Wu, W., Kuča, K., & Adam, V. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01292-6 · Cited by 518
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Viganó, S., Alatzoglou, D., Irving, M. B., Ménétrier‐Caux, C., Caux, C., Romero, P. J., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 434
Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
Self-citation
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.016 · Cited by 300
Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects
Meng, L., Cheng, Y., Tong, X., Gan, S., Ding, Y., Zhang, Y., Wang, C., Xu, L., Zhu, Y., Wu, J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b03590 · Cited by 270
The role of hypoxia‐inducible factor 1 in tumor immune evasion
Li, Y., Wu, W., Wang, X., Fang, L., Adam, V., Nepovimová, E., Wu, Q., & Kuča, K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21771 · Cited by 276
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
Bailly, C., Thuru, X., & Quesnel, B. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa002 · Cited by 256
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy
Zhang, J., Dang, F., Ren, J., & Wei, W. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.09.004 · Cited by 233
Enhancing Triple Negative Breast Cancer Immunotherapy by ICG‐Templated Self‐Assembly of Paclitaxel Nanoparticles
Feng, B., Niu, Z., Hou, B., Zhou, L., Li, Y., & Yu, H. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201906605 · Cited by 214
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1
Roux, C., Jafari, S. M., Shinde, R. S., Duncan, G. S., Cescon, D. W., Silvester, J., Chu, M. F., Hodgson, K., Berger, T., Wakeham, A. C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819473116 · Cited by 208
Targeting Adenosine Receptor Signaling in Cancer Immunotherapy
Sek, K., Mølck, C., Stewart, G. D., Kats, L. M., Darcy, P. K., & Beavis, P. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123837 · Cited by 206
Antibody–drug conjugates: in search of partners of choice
Fuentes‐Antrás, J., Genta, S., Vijenthira, A., & Siu, L. L. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.01.003 · Cited by 207
CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint
Yu, M., Guo, G. F., Huang, L., Deng, L., Chang, C.-S., Achyut, B. R., Canning, M. T., Xu, N., Arbab, A. S., Bollag, R. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14060-x · Cited by 196
Hypoxia-inducible factors and innate immunity in liver cancer
Yuen, V. W., & Wong, C. C. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137553 · Cited by 187
RETRACTED: Cancer-Associated Fibroblasts-Derived Exosomes Suppress Immune Cell Function in Breast Cancer via the miR-92/PD-L1 Pathway
Dou, D., Ren, X., Han, M., Xu, X., Ge, X., Gu, Y., & Wang, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02026 · Cited by 175
Retracted
Targeting CD73 to augment cancer immunotherapy
Roh, M., Wainwright, D. A., Wu, J. D., Wan, Y., & Zhang, B. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.001 · Cited by 165
Targeting the CD73-adenosine axis in immuno-oncology
Allard, D., Chrobák, P., Allard, B., Messaoudi, N., & Stagg, J. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.05.001 · Cited by 161
Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis
Hu, T., Liu, H., Liang, Z., Wang, F., Zhou, C., Zheng, X., Zhang, Y., Song, Y., Hu, J., He, X., et al. (2020) · Theranostics · doi:10.7150/thno.40860 · Cited by 160
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers
Kong, T., Ahn, R., Yang, K., Zhu, X., Fu, Z., Morin, G., Bramley, R., Cliffe, N. C., Xue, Y., Kuasne, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1108 · Cited by 162
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy
Liu, J., Zhao, Z., Qiu, N., Zhou, Q., Wang, G., Jiang, H., Piao, Y., Zhou, Z., Tang, J., & Shen, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-22407-6 · Cited by 154
CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma
Ma, X.-L., Hu, B., Tang, W.-G., Xie, S.-H., Ren, N., Guo, L., & Lu, R.-Q. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-0845-z · Cited by 147
CD47/SIRPα axis: bridging innate and adaptive immunity
van Duijn, A. V. D. P. , van der Burg, S. H., & Scheeren, F. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004589 · Cited by 151
Role of hypoxia in the tumor microenvironment and targeted therapy
Chen, G., Wu, K., Li, H., Xia, D., & He, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961637 · Cited by 148
Self-citation
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
Lan, J., Lu, H., Samanta, D., Salman, S., Lü, Y., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809695115 · Cited by 127
Self-citation
Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion
Wang, Z., Li, B., Li, S., Lin, W., Wang, Z., Wang, S., Chen, W., Shi, W., Chen, T., Zhou, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34064-4 · Cited by 123
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Inhibition of Immunosuppressive Tumors by Polymer‐Assisted Inductions of Immunogenic Cell Death and Multivalent PD‐L1 Crosslinking
Li, L., Li, Y., Yang, C., Radford, D. C., Wang, J., Janat-Amsbury, M.-M., Kopec̆ek, J., & Yang, J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201908961 · Cited by 119
Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints
Lequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.021 · Cited by 117
HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
Salman, S., Meyers, D. J., Wicks, E. E., Lee, S. N., Datan, E., Thomas, A. M., Anders, N. M., Hwang, Y., Lyu, Y., Yang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156774 · Cited by 111
“Acriflavine treatment of tumor-bearing mice was recently reported to increase intratumoral CD8+ T cells and NK cells (42, 43).”
BackgroundSelf-citation
An in situ hydrogel-mediated chemo-immunometabolic cancer therapy
Wang, B., Chen, J., Caserto, J. S., Wang, X., & Ma, M. (2022) · Nature Communications · doi:10.1038/s41467-022-31579-8 · Cited by 111
CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
Bouwstra, R., van Meerten, T., & Bremer, E. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.943 · Cited by 111
Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases
Mu, X., Zhang, M., Wei, A., Yin, F., Wang, Y., Hu, K., & Jiang, J. (2021) · Nanoscale · doi:10.1039/d0nr08024a · Cited by 106
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
Santarpía, M., Aguilar, A., CHAIB-OUKADOUR, I., Cardona, A. F., Fancelli, S., Laguía, F., Bracht, J. W. P., Cao, P., Molina‐Vila, M. Á., Karachaliou, N., et al. (2020) · Cancers · doi:10.3390/cancers12061475 · Cited by 102
Carrier-free nanoassembly of doxorubicin prodrug and siRNA for combinationally inducing immunogenic cell death and reversing immunosuppression
Chen, S., Li, D., Du, X., He, X., Huang, M., Wang, Y., Yang, X., & Wang, J. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100924 · Cited by 99
Oxygen‐Evolving Manganese Ferrite Nanovesicles for Hypoxia‐Responsive Drug Delivery and Enhanced Cancer Chemoimmunotherapy
Yang, K., Yu, G., Tian, R., Zhou, Z., Deng, H., Li, L., Yáng, Z., Zhang, G., Liu, D., Wei, J., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202008078 · Cited by 97
Nanomedicine Strategies in Conquering and Utilizing the Cancer Hypoxia Environment
Pan, Y., Liu, L., Mou, X., & Cai, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c07763 · Cited by 98
Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients
Chen, J., Zheng, D.-X., Yu, X.-J., Sun, H.-W., Xu, Y.-T., Zhang, Y., & Xu, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1652540 · Cited by 94
Platelet-armored nanoplatform to harmonize janus-faced IFN-γ against tumor recurrence and metastasis
Li, Q., Zhou, Y., He, W., Ren, X., Zhang, M., Jiang, Y., Zhou, Z., & Luan, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.08.020 · Cited by 93
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
Lu, H., Tran, T. M. L., Park, Y., Chen, I., Lan, J., Xie, Y., & Semenza, G. L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0270 · Cited by 96
Self-citation
Hypoxia‑inducible factors in hepatocellular carcinoma (Review)
Guo, Y., Xiao, Z., Liu, Y., Gao, Y., Zhu, Q., Hu, L., Huang, D., & Xu, Q. (2019) · Oncology Reports · doi:10.3892/or.2019.7397 · Cited by 93
The Immunosuppressive Microenvironment in BRCA1-IRIS–Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages
Sami, E., Paul, B. T., Koziol, J. A., & ElShamy, W. M. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2374 · Cited by 90
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 88
JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer
Tian, Y., Wang, X., Zhao, S., Liao, X., Younis, M. R., Wang, S., Zhang, C., & Lu, G. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b18730 · Cited by 89
Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade
Choi, Y., Seok, S. H., Yoon, H. Y., Ryu, J. H., & Kwon, I. C. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115306 · Cited by 92
Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy
Davis, L., Recktenwald, M., Hutt, E., Fuller, S., Briggs, M., Goel, A., & Daringer, N. (2022) · Cancers · doi:10.3390/cancers14051259 · Cited by 83
Deciphering the role of CD47 in cancer immunotherapy
Liu, Y., Weng, L., Wang, Y., Zhang, J., Wu, Q., Zhao, P., Shi, Y., Wang, P., & Fang, L. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.10.009 · Cited by 87
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Principe, D. R., Kamath, S. D., Korc, M., & Munshi, H. G. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108111 · Cited by 83
siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion
Ngamcherdtrakul, W., & Yantasee, W. (2019) · Translational research · doi:10.1016/j.trsl.2019.08.005 · Cited by 81
Thymosin α-1 Reverses M2 Polarization of Tumor-Associated Macrophages during Efferocytosis
Wei, Y.-T., Wang, X.-R., Yan, C., Huang, F., Zhang, Y., Liu, X., Wen, Z.-F., Sun, X.-T., Zhang, Y., Chen, Y.-Q., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4260 · Cited by 80
Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments
Wang, W., Zheng, H., Jiang, J., Li, Z., Jiang, D., Shi, X., Wang, H., Jiang, J., Xie, Q., Gao, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32066-w · Cited by 81
The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells
Lin, Q., Wang, X., & Hu, Y. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216318 · Cited by 78
Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers
Xu, T., Yu, S., Zhang, J., & Wu, S. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01198-9 · Cited by 78
Hypoxia-inducible factor in breast cancer: role and target for breast cancer treatment
Zhi, S., Chen, C., Huang, H., Zhang, Z., Zeng, F., & Zhang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1370800 · Cited by 91
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review
Pellegrino, B., Musolino, A., Llop‐Guevara, A., Serra, V., Silva, P. D., Hlavata, Z., Sangiolo, D., Willard-Gallo, K. E., & Solinas, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.010 · Cited by 77
The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?
Khouzam, R. A., Zaarour, R. F., Brodaczewska, K. K., Azakir, B., Venkatesh, G. H., Thiery, J., Terry, S., & Chouaı̈b, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828875 · Cited by 80
IL-17–CXC Chemokine Receptor 2 Axis Facilitates Breast Cancer Progression by Up-Regulating Neutrophil Recruitment
Wu, L., Awaji, M. I., Saxena, S., Varney, M. L., Sharma, B., & Singh, R. K. (2019) · American Journal Of Pathology · doi:10.1016/j.ajpath.2019.09.016 · Cited by 75
Breast cancer–associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells
Gómez, V., Eykyn, T. R., Mustapha, R., Flores‐Borja, F., Male, V. H., Barber, P. R., Patsialou, A., Green, R. J., Panagaki, F., Li, C. W., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aax4585 · Cited by 77
CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer
Petruk, N., Tuominen, S., Åkerfelt, M., Mattsson, J., Sandholm, J. A., Nees, M., Yegutkin, G. G., Jukkola‐Vuorinen, A., Tuomela, J. M., & Selander, K. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-85379-z · Cited by 80
Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma
Wang, F., Huang, Q., Su, H., Sun, M., Wang, Z., Chen, Z., Zheng, M., Chakroun, R. W., Monroe, M. K., Chen, D., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204621120 · Cited by 76
Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer
Zhou, F., Gao, J., Xu, Z., Li, T., Gao, A., Sun, F. Z., Wang, F., Wang, W., Geng, Y., Zhang, F., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101025 · Cited by 71
The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy
Li, Z., Li, Y., Gao, J., Fu, Y., Hua, P., Jing, Y., Cai, M., Wang, H., & Tong, T. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119150 · Cited by 76
Ionizing Radiation Triggers the Antitumor Immunity by Inducing Gasdermin E-Mediated Pyroptosis in Tumor Cells
Cao, W., Chen, G., Wu, L., Yu, K. N., Sun, M., Yang, M., Jiang, Y., Jiang, Y., Yuan, X., Peng, S., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.07.1841 · Cited by 74
Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.11.001 · Cited by 71
Self-citation
Hypoxia-Induced Phenotypes that Mediate Tumor Heterogeneity
Qian, J., & Rankin, E. B. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_3 · Cited by 73
Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment
Yang, M., Qin, C., Tao, L., Cheng, G., Li, J., Lv, F., Yang, N., Xing, Z., Chu, X., Han, X., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122253 · Cited by 75
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 71
Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6Chigh Myeloid Cells
Wu, C., Tan, X., Hu, X., Zhou, M., Yan, J., & Ding, C. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900930 · Cited by 70
The Clinical Significance of CD73 in Cancer
Bach, N., Winzer, R., Tolosa, E., Fiedler, W., & Brauneck, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411759 · Cited by 74
Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD‐L1 Expression for Circumventing Immune Resistance of Cancer
Zhou, F., Gao, J., Tang, Y., Zou, Z., Jiao, S., Zhou, Z., Xu, H., Xu, Z. P., Yu, H., & Xu, Z. (2021) · Advanced Materials · doi:10.1002/adma.202102668 · Cited by 67
Curcumin-human serum albumin nanoparticles decorated with PDL1 binding peptide for targeting PDL1-expressing breast cancer cells
Hasanpoor, Z., Mostafaie, A., Nikokar, I., & Hassan, Z. M. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.04.130 · Cited by 65
Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47
Tan, W., Tang, H., Jiang, X., Ye, F., Huang, L., Shi, D., Li, L., Huang, X., Li, L., Xie, X., et al. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14462 · Cited by 65
The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome
Redfern, A. D., Spalding, L. J., & Thompson, E. W. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9906-x · Cited by 64
Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors
Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64
Self-citation
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
Gilad, Y., Eliaz, Y., Yu, Y., Han, S. J., O’Malley, B. W., & Lonard, D. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-51537-7 · Cited by 64
CD73, Tumor Plasticity and Immune Evasion in Solid Cancers
Yang, H., Yao, F., Davis, P. F., Tan, S. T., & Hall, S. R. R. (2021) · Cancers · doi:10.3390/cancers13020177 · Cited by 65
Targeted Regulation of Blood–Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma
Meng, L., Wang, C., Lu, Y., Sheng, G., Yang, L., Wu, Z., Xu, H., Han, C., Lu, Y., & Han, F. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c00347 · Cited by 61
Stimuli-responsive nano vehicle enhances cancer immunotherapy by coordinating mitochondria-targeted immunogenic cell death and PD-L1 blockade
Li, Q., Chen, C., Kong, J., Li, L., Li, J., & Huang, Y. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.005 · Cited by 62
Infectious Bronchitis Virus (Gammacoronavirus) in Poultry Farming: Vaccination, Immune Response and Measures for Mitigation
Bhuiyan, M. S. A., Amin, Z., Rodrigues, K. F., Saallah, S., Shaarani, S. M., Sarker, S., & Siddiquee, S. (2021) · Veterinary Sciences · doi:10.3390/vetsci8110273 · Cited by 65
Drugs targeting adenosine signaling pathways: A current view
Kutryb-Zając, B. A., Kawecka, A., Nasadiuk, K., Braczko, A., Stawarska, K., Caiazzo, E., Koszałka, P., & Cicala, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115184 · Cited by 62
Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy
Feliz‐Mosquea, Y. R., Christensen, A. A., Wilson, A. S., Westwood, B. M., Varagić, J., Meléndez, G. C., Schwartz, A. L., Chen, Q., Griner, L. A. M., Guha, R., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4884-x · Cited by 58
Hypoxia-Regulated Tumor-Derived Exosomes and Tumor Progression: A Focus on Immune Evasion
Shao, X., Hua, S., Feng, T., Ocansey, D. K. W., & Yin, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911789 · Cited by 60
Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells
Camorani, S., Tortorella, S., Agnello, L., Spanu, C., d’Argenio, A., Nilo, R., Zannetti, A., Locatelli, E., Fedele, M., Franchini, M. C., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102225 · Cited by 56
Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73
Jarvis, L. B., Rainbow, D. B., Coppard, V., Howlett, S., Georgieva, Z. G., Davies, J. L., Mullay, H. K., Hester, J., Ashmore, T., van den Bosch, A. M. R., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02721-x · Cited by 60
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Wang, H., Ma, H., Sové, R. J., Emens, L. A., & Popel, A. S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002100 · Cited by 59
Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity
Piovesan, D., Tan, J. B. L., Becker, A., Banuelos, J., Narasappa, N., DiRenzo, D. M., Zhang, K., Chen, A., Ginn, E., Udyavar, A. R., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0802 · Cited by 53
Inside the stemness engine: Mechanistic links between deregulated transcription factors and stemness in cancer
Ervin, E.-H., French, R., Chang, C., & Pauklin, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.001 · Cited by 53
Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade
Zhou, M., Luo, C., Zhou, Z., Li, L., & Huang, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.04.029 · Cited by 50
BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy
Samanta, D., Huang, T. Y.-T., Shah, R., Yang, Y., Pan, F., & Semenza, G. L. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108073 · Cited by 49
Self-citation
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition
Al‐Sudani, H., Ni, Y., Jones, P., Karakilic, H., Cui, L. G., Johnson, L. D. S., Rose, P. G., Olawaiye, A. B., Edwards, R. P., Uger, R. A., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-023-00418-4 · Cited by 52
Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy
Song, C. W., Kim, H., Kim, M.-S., Park, H. J., Paek, S.-H., Terezakis, S. A., & Cho, L. C. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.255 · Cited by 58
Concurrent Expression of CD47 and CD44 in Colorectal Cancer Promotes Malignancy
Fujiwara‐Tani, R., Sasaki, T., Ohmori, H., Luo, Y., Goto, K., Nishiguchi, Y., Mori, S., Nakashima, C., Mori, T., Miyagawa, Y., et al. (2019) · Pathobiology · doi:10.1159/000496027 · Cited by 48
Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives
Jiang, C., Sun, H., Jiang, Z., Tian, W., Cang, S., & Yu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1378647 · Cited by 48
Triple-negative breast cancer: new treatment strategies in the era of precision medicine
Wu, S., Wang, H., Shao, Z., & Jiang, Y. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1714-8 · Cited by 50
Engineering nanoparticles boost TNBC therapy by CD24 blockade and mitochondrial dynamics regulation
Zhao, M. F., Li, J., Chen, F., Han, Y., Chen, D., & Hu, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.075 · Cited by 46
Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.06.001 · Cited by 50
Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy
Li, J., Zhao, M. F., Liang, W., Wu, S., Wang, Z., & Wang, D. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.015 · Cited by 46
Targeting intratumoral hypoxia to enhance anti-tumor immunity
Semenza, G. L. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.09.002 · Cited by 47
Self-citation
Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities
Rosell, R., Cardona, A. F., Arrieta, O. G., Aguilar, A., Ito, M., Pedraz‐Valdunciel, C., Codony‐Servat, J., & Santarpía, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01519-2 · Cited by 48
Programming Injectable DNA Hydrogels Yields Tumor Microenvironment‐Activatable and Immune‐Instructive Depots for Augmented Chemo‐Immunotherapy
Fan, Y., Zhan, M., Junhao, L., Yang, X., Zhang, B., Shi, X., & Hu, Y. M. (2023) · Advanced Science · doi:10.1002/advs.202302119 · Cited by 45

Authors: Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L.
Affiliations: Johns Hopkins University (US)
Corresponding author: Semenza, Gregg L.
ORCID: Ni, Xuhao
Li, Huili
Zahnow, Cynthia A.
Gabrielson, Edward
Pan, Fan
Semenza, Gregg L.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2018-01-24
Volume: 115
Issue: 6
Pages: E1239-E1248
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1718197115
PMC: PMC5819443
OpenAlex: W2785041354
Cited by: 302
References: 63
Citations by year: 2026: 13 · 2025: 19 · 2024: 35 · 2023: 47 · 2022: 53 · 2021: 45 · 2020: 43 · 2019: 28 · 2018: 17
FWCI: 12.50
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.pnas.org/site/aboutpnas/licenses.xhtml (vor, 181 d)
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Emerson Collective Cancer Research Fund (n/a)
American Cancer Society (RP-16-239-06-COUN)
Cindy Rosencrans Fund for Triple Negative Breast Cancer (n/a)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: triple-negative breast cancer, chemoresistance, immune evasion, CD47, CD73, PD-L1, hypoxia-inducible factor, HIF inhibitors, tumor immune evasion, tumor cell survival
MeSH terms: Animals, Antineoplastic Agents, Female, Humans, Mice, Inbred BALB C, Mice, Inbred C57BL, T-Lymphocytes, Tumor Cells, Cultured, 5'-Nucleotidase, Gene Expression Regulation, Neoplastic, Apoptosis, Tumor Escape, Xenograft Model Antitumor Assays, Mice, Hypoxia-Inducible Factor 1, CD47 Antigen, GPI-Linked Proteins, B7-H1 Antigen, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks